Encorafenib

468 interactions 398 cited references
Also sold as: Braftovi Braftovi®
About Encorafenib

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the bod… Read the full Encorafenib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Atazanavir Posaconazole Ranolazine Piperaquine Doravirine Pimozide
36 Contraindicated 392 Major 40 Moderate
All (468) Contraindicated (36) Major (392) Moderate (40)

Major

Encorafenib Abametapir Increased exposure of CYP3A4 substrate Details Encorafenib Amitriptyline Elavil Increased risk of QT interval prolongation Details Encorafenib Sertraline Increased risk of QT interval prolongation Details Encorafenib Buprenorphine Belbuca Increased risk of QT interval prolongation Details Encorafenib Relugolix Orgovyx Increased risk of QT interval prolongation Details Encorafenib Simvastatin Flolipid Altered (increased/reduced) simvastatin exposure, an increased risk of simvastatin-related toxicities and reduced efficacy of simv... Details Encorafenib Abemaciclib Verzenio Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Acalabrutinib Calquence Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Alpelisib Piqray Altered alpelisib exposure, an increased risk of alpelisib-related adverse effects and toxicity and reduced efficacy of alpelisib Details Encorafenib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Encorafenib Apixaban Eliquis Reduced apixaban exposure Details Encorafenib Apremilast Otezla Reduced apremilast exposure and an reduced efficacy of apremilast Details Encorafenib Arsenic Trioxide Trisenox Increased risk of QT interval prolongation Details Encorafenib Aripiprazole Injection Abilify Reduced ARIPiprazole or ARIPiprazole lauroxil (prodrug of ARIPiprazole) exposure and an increased risk of QT interval prolongation Details Encorafenib Arsenic Trioxide Injection Trisenox Increased risk of QT interval prolongation Details Encorafenib Asciminib Scemblix Reduced asciminib exposure and reduced efficacy of asciminib Details Encorafenib Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Encorafenib Atogepant Qulipta Altered atogepant exposure Details Encorafenib Avapritinib Ayvakit Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Azithromycin AzaSite Increased risk of QT interval prolongation Details Encorafenib Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Encorafenib Alfuzosin UroXatral Increased risk of QT interval prolongation Details Encorafenib Amlodipine Amvaz® Reduced amLODIPine exposure Details Encorafenib Anagrelide Agrylin Increased risk of QT interval prolongation Details Encorafenib Avanafil Stendra Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Bedaquiline Sirturo Increased risk of QT interval prolongation Details Encorafenib Bosutinib Bosulif Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Brexpiprazole Rexulti Reduced brexpiprazole exposure Details Encorafenib Budesonide Entocort Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Budesonide Nasal Spray Rhinocort Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Budesonide Oral Inhalation Pulmicort Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Encorafenib Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Encorafenib Chloroquine Aralen® Increased risk of QT interval prolongation Details Encorafenib Cobimetinib Cotellic Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Cyclosporine Injection Atopica Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Cyclosporine Ophthalmic Cequa Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Dasatinib Phyrago Reduced CYP3A4 substrate exposure, reduced efficacy of CYP3A4 substrate and an increased risk of QT interval prolongation Details Encorafenib Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Encorafenib Deutetrabenazine Austedo Increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.